Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer

作者：Laure Dossus, Stella Koutros, Douglas F. Easton, Audrey Jung, Sarah Van Alsten, Catriona McLean, Kristan J. Aronson, Hiltrud Brauch, Marjanka K. Schmidt, Alpa V Patel, Helena Jernström, Sabine Behrens, Arto Mannermaa, Laura E. Beane Freeman, Mustapha Abubakar, Lauren R. Teras, Christopher A. Haiman, Kamila Czene, James V. Lacey, Melissa C. Southey, Nadia Obi, Paul D. P. Pharoah, R. Kaaks, Charles M. Perou, Pooja Middha, Wang, Qin, Hermann Brenner, Montserrat García‐Closas, Renée T. Fortner, Anna H. Wu, Wei Zheng, Jennifer Stone, Peter Kraft, Shamim Shahi, Annelie Augustinsson, Xiao-Ou Shu, Kyriaki Michailidou, Rachel A. Murphy, D. Gareth Evans, Roger L. Milne, Bernd Holleczek, Melissa A. Troester, Celine M. Vachon, Gad Rennert, Pascal Guénel, Jenny Chang-Claude, P.F. Hall, Mihalis I. Panayiotidis, A. Heather Eliassen, Katerina Shulman, Ahearn, Thomas U., Reiner Hoppe, Clara Bodelón, Manjeet K. Bolla, Thérèse Truong, Alicja Wolk, Charlotte Le Cornet · 发表于：UNC Libraries · 年份：2025 · DOI：10.17615/25en-df58 · 研究领域：Cancer Risks and Factors、Breast Cancer Treatment Studies、BRCA gene mutations in cancer

Etiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood. To examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes. This study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024. MHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use). Breast cancer intrinsic-like subtypes (luminal A–like, luminal B–like, luminal B–ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched–like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in...